相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data
Masataka Kuwana et al.
MODERN RHEUMATOLOGY (2023)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
Bhavani Shankara Bagepally et al.
BMC HEALTH SERVICES RESEARCH (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis
Chongqing Tan et al.
CLINICAL RHEUMATOLOGY (2022)
Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis
Aliki I. Venetsanopoulou et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience
Behzad Fatemi et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
So-Young Ha et al.
RHEUMATOLOGY AND THERAPY (2021)
Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population
Chongqing Tan et al.
ADVANCES IN THERAPY (2021)
Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis
Mariana Del Grossi Paglia et al.
PLOS ONE (2021)
Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
SiNi Li et al.
RHEUMATOLOGY AND THERAPY (2021)
Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
SiNi Li et al.
RHEUMATOLOGY AND THERAPY (2021)
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Sabine E. Grimm et al.
PHARMACOECONOMICS (2021)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
F. Navarro et al.
CLINICAL RHEUMATOLOGY (2020)
Why it's Time to Abandon the ICER
Mike Paulden
PHARMACOECONOMICS (2020)
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
Bhavani Shankara Bagepally et al.
BMJ OPEN DIABETES RESEARCH & CARE (2020)
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
Lei Tian et al.
PHARMACOECONOMICS (2020)
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
Celine J. Van De Laar et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2020)
2018 update of the APLAR recommendations for treatment of rheumatoid arthritis
Chak Sing Lau et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
Noemi Muszbek et al.
ADVANCES IN THERAPY (2019)
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
Der-Yuan Chen et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
Bhavani Shankara Bagepally et al.
VALUE IN HEALTH (2019)
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
Marie Fournier et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
Max Schlueter et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States
Lindsay Claxton et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Lesley Uttley et al.
PHARMACOECONOMICS (2018)
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Shijie Ren et al.
PHARMACOECONOMICS (2018)
The GRADE Working Group clarifies the construct of certainty of evidence
Monica Hultcrantz et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2017)
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Roy Fleischmann et al.
LANCET (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators
Jeroen P. Jansen et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Risk of bias in model-based economic evaluations: the ECOBIAS checklist
Charles Christian Adarkwah et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
Vibeke Strand et al.
RHEUMATOLOGY (2016)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
Min-Young Lee et al.
CLINICAL THERAPEUTICS (2015)
Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening
James F. O'Mahony et al.
VALUE IN HEALTH (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis
SC Bae et al.
RHEUMATOLOGY (2003)
分享论文
